QL-415 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Hematological Tumor. According to GlobalData, Phase I drugs for Hematological Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the QL-415 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
QL-415 is under development for the treatment of advanced, recurrent, metastatic solid and hematological tumors. It is administered through subcutaneous route and acts by targeting PD-L1 and IL-15.
For a complete picture of QL-415’s drug-specific PTSR and LoA scores, buy the report here.